Literature DB >> 21239999

Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.

Lin Li1, Suiyi Tan, Hong Lu, Lu Lu, Jie Yang, Hong Jin, Shuwen Liu, Shibo Jiang.   

Abstract

BACKGROUND: The development of a safe, effective, and affordable microbicide to prevent the sexual transmission of HIV combination is urgently needed. Our previous studies demonstrated that 3-hydroxyphthalic anhydride-modified chicken ovalbumin (HP-OVA) exhibited potent antiviral activity against a broad spectrum of HIV, simian immunodeficiency virus, and herpes simplex virus, making it a promising candidate as a component of combination microbicide. We intended to evaluate potential the synergistic anti-HIV-1 effect of HP-OVA in combination with antiretroviral drug (ARV)-based microbicide candidates.
METHODS: The antiviral activity of HP-OVA and the ARVs, including HIV-1 entry inhibitors (T20, C52L, NB64, NBD556, AMD3100, and Maraviroc) and reverse transcriptase inhibitors (Tenofovir, UC781, and TMC120), tested alone or in combination, against HIV-1 X4 and R5 viruses, including some drug-resistant strains, was determined in MT-2 and peripheral blood mononuclear cells using p24 assay. The immune responses induced by HP-OVA that was applied in the vaginas of rats were detected by enzyme-linked immunosorbent assay.
RESULTS: When each of these ARV-based microbicide candidates was combined with HP-OVA, synergistic activity was observed against infection by both X4 and R5 strains, and the degree of synergy differed in each case. HP-OVA was highly effective against several ARV-resistant HIV-1 strains, suggesting that combining HP-OVA with these ARV-based microbicide candidates might work cooperatively against both drug-sensitive and -resistant HIV-1 strains. Human body fluids and human proteins had little or no effects on HP-OVA-mediated inhibitory activity against HIV-1 infection. HP-OVA formulated in the universal gel maintained its antiviral activity for at least 1 month and only induced weak immune responses after its multiple applications in the vaginas of rats.
CONCLUSIONS: Synergistic and complementary effects against infection by a broad spectrum of HIV-1 strains were observed by combining HP-OVA with the ARV-based microbicide candidates. These findings provide a sound scientific platform for the development of a safe, effective, and affordable combination microbicide to prevent the sexual transmission of HIV and other sexually transmissible viruses.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21239999      PMCID: PMC3084366          DOI: 10.1097/QAI.0b013e31820a4a8d

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  42 in total

1.  Scientists rethink approach to HIV gels.

Authors:  Erika Check
Journal:  Nature       Date:  2007-03-01       Impact factor: 49.962

2.  Protein design of a bacterially expressed HIV-1 gp41 fusion inhibitor.

Authors:  Yiqun Deng; Qi Zheng; Thomas J Ketas; John P Moore; Min Lu
Journal:  Biochemistry       Date:  2007-03-20       Impact factor: 3.162

3.  Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.

Authors:  Patrick Dorr; Mike Westby; Susan Dobbs; Paul Griffin; Becky Irvine; Malcolm Macartney; Julie Mori; Graham Rickett; Caroline Smith-Burchnell; Carolyn Napier; Rob Webster; Duncan Armour; David Price; Blanda Stammen; Anthony Wood; Manos Perros
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  Carrageenan/MIV-150 (PC-815), a combination microbicide.

Authors:  José A Fernández-Romero; Mitchell Thorn; Stuart G Turville; Kanani Titchen; Kristin Sudol; Jifan Li; Todd Miller; Melissa Robbiani; Robin A Maguire; Robert W Buckheit; Tracy L Hartman; David M Phillips
Journal:  Sex Transm Dis       Date:  2007-01       Impact factor: 2.830

5.  Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates.

Authors:  Hong Lu; Qian Zhao; Greg Wallace; Shuwen Liu; Yuxian He; Robin Shattock; A Robert Neurath; B Shibo Jiang
Journal:  AIDS Res Hum Retroviruses       Date:  2006-05       Impact factor: 2.205

Review 6.  Microbicide drug candidates to prevent HIV infection.

Authors:  Jan Balzarini; Lut Van Damme
Journal:  Lancet       Date:  2007-03-03       Impact factor: 79.321

7.  Acceptability of tenofovir gel as a vaginal microbicide by US male participants in a Phase I clinical trial (HPTN 050).

Authors:  Alex Carballo-Diéguez; Iván C Balán; Kathleen Morrow; Rochelle Rosen; Joanne E Mantell; Fang Gai; Susie Hoffman; Lisa Maslankowski; Wafaa El-Sadr; Kenneth Mayer
Journal:  AIDS Care       Date:  2007-09

8.  Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women.

Authors:  Kenneth H Mayer; Lisa A Maslankowski; Fang Gai; Wafaa M El-Sadr; Jessica Justman; Antonia Kwiecien; Benoît Mâsse; Susan H Eshleman; Craig Hendrix; Kathleen Morrow; James F Rooney; Lydia Soto-Torres
Journal:  AIDS       Date:  2006-02-28       Impact factor: 4.177

9.  Entry inhibitor-based microbicides are active in vitro against HIV-1 isolates from multiple genetic subtypes.

Authors:  Thomas J Ketas; Susan M Schader; Juan Zurita; Esther Teo; Victoria Polonis; Min Lu; Per Johan Klasse; John P Moore
Journal:  Virology       Date:  2007-04-10       Impact factor: 3.616

10.  Role of seminal plasma in the anti-HIV-1 activity of candidate microbicides.

Authors:  A Robert Neurath; Nathan Strick; Yun-Yao Li
Journal:  BMC Infect Dis       Date:  2006-10-16       Impact factor: 3.090

View more
  3 in total

1.  ADS-J1 inhibits semen-derived amyloid fibril formation and blocks fibril-mediated enhancement of HIV-1 infection.

Authors:  Tianrong Xun; Wenjuan Li; Jinquan Chen; Fei Yu; Wei Xu; Qian Wang; Ruizhe Yu; Xiaojuan Li; Xuefeng Zhou; Lu Lu; Shibo Jiang; Lin Li; Suiyi Tan; Shuwen Liu
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

2.  Efficacy, stability, and biosafety of sifuvirtide gel as a microbicide candidate against HIV-1.

Authors:  Liangzhu Li; Yinyin Ben; Songhua Yuan; Shibo Jiang; Jianqing Xu; Xiaoyan Zhang
Journal:  PLoS One       Date:  2012-05-16       Impact factor: 3.240

3.  Myricetin antagonizes semen-derived enhancer of viral infection (SEVI) formation and influences its infection-enhancing activity.

Authors:  Ruxia Ren; Shuwen Yin; Baolong Lai; Lingzhen Ma; Jiayong Wen; Xuanxuan Zhang; Fangyuan Lai; Shuwen Liu; Lin Li
Journal:  Retrovirology       Date:  2018-07-16       Impact factor: 4.602

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.